These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9397201)

  • 41. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
    Yates DR; Rouprêt M; Drouin SJ; Comperat E; Ricci S; Lacave R; Sèbe P; Cancel-Tassin G; Bitker MO; Cussenot O
    Prostate; 2012 Sep; 72(12):1382-8. PubMed ID: 22228175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
    Queiroz MA; Viana P; Santos A; Bastos D; Etchebehere E; Cerri G
    Clin Nucl Med; 2016 Sep; 41(9):e417-9. PubMed ID: 27276202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I; Maurer T; Souvatzoglou M; Beer AJ; Vag T; Wirtz M; Weirich G; Wester HJ; Gschwend JE; Schwaiger M; Schottelius M; Eiber M
    Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical role of prostate-specific membrane antigen (PSMA).
    Chang SS; Heston WD
    Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PROSTASCINT scan for staging prostate cancer.
    Lange PH
    Urology; 2001 Mar; 57(3):402-6. PubMed ID: 11248606
    [No Abstract]   [Full Text] [Related]  

  • 51. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
    Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
    Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
    Pereira Mestre R; Treglia G; Ferrari M; Pascale M; Mazzara C; Azinwi NC; Llado' A; Stathis A; Giovanella L; Roggero E
    Eur J Clin Invest; 2019 Mar; 49(3):e13063. PubMed ID: 30580449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Minner S; Wittmer C; Graefen M; Salomon G; Steuber T; Haese A; Huland H; Bokemeyer C; Yekebas E; Dierlamm J; Balabanov S; Kilic E; Wilczak W; Simon R; Sauter G; Schlomm T
    Prostate; 2011 Feb; 71(3):281-8. PubMed ID: 20809553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
    Su HC; Zhu Y; Ling GW; Hu SL; Xu XP; Dai B; Ye DW
    Asian J Androl; 2017; 19(3):267-271. PubMed ID: 27976632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    BJU Int; 2005 Aug; 96(3):303-7. PubMed ID: 16042718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
    Ponsky LE; Cherullo EE; Starkey R; Nelson D; Neumann D; Zippe CD
    Prostate Cancer Prostatic Dis; 2002; 5(2):132-5. PubMed ID: 12497003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
    Xu T; Chen X; Wang XF; Hou SK; Zhu JC; Zhang XD; Huang XB
    Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):164-8. PubMed ID: 15100735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical impact of
    Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
    De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F
    Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?
    Gomez P; Manoharan M; Kim SS; Soloway MS
    BJU Int; 2004 Aug; 94(3):299-302. PubMed ID: 15291855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.